Our findings align with previous research in ovarian cancer, specifically serous adenocarcinoma, where ACTN4 gene amplification has been linked to increased actinin‐4 protein immunoreactivity [18]. This evidence concerns the gene ACTN4 and serous adenocarcinoma.